市場調査レポート

商品コード

1562463

ゲノム編集の市場規模、シェア、成長分析、技術別、デリバリー方法別、用途別、モード別、最終用途別、地域別 - 産業予測、2024年～2031年

Genome Editing Market Size, Share, Growth Analysis, By Technology (/Cas9, TALENs/MegaTALs), By Delivery Method, By Application, By Mode, By End-use, By Region - Industry Forecast 2024-2031

出版日: 2024年09月11日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 778,888円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 911,152円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,043,416円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.96円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ゲノム編集の世界市場規模は2022年に77億米ドルと評価され、2023年の89億9,000万米ドルから2031年には311億5,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは16.80％で成長する見通しです。

ゲノム編集は、遺伝的形質を変えるために配列を切断したり追加したり削除したりすることによって、生物のDNAを改変することを含みます。この技術は、ゲノムを正確に変化させることで、細胞に特定の特性を持たせることを目的としています。世界各国の政府は、公的機関や民間企業、学術機関への資金提供や賞の授与により、KEYWORD調査への投資を増やしています。このような支援の増加が、予測期間中のゲノム編集市場のプラス成長の原動力となっています。ゲノム編集市場の拡大にはいくつかの要因が寄与しています。これには、がんや遺伝性疾患の有病率の上昇、個別化医療への嗜好の高まり、研究開発費の増加、バイオテクノロジーや製薬業界の進歩などが含まれます。民間および公的資金の急増、シーケンス技術の急速な進歩、ゲノム編集技術の進歩も主要な促進要因です。市場は、CRISPR技術の採用や、様々なバイオテクノロジー分野での合成遺伝子に対する需要の高まりから大きな影響を受けています。さらに、市場競争激化がゲノム編集市場の成長を加速させています。例えば、Vertex Pharmaceuticals社が2021年4月にCRISPR Therapeutics社と9億米ドルを投じて、βサラセミアと鎌状赤血球症に対するCRISPR-Cas9遺伝子編集療法の開発と商業化に合意したことは、この分野のダイナミックな性質を裏付けています。このような投資やイニシアチブは、ゲノム編集市場の成長をさらに促進すると予想されます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Merck KGaA（Germany）
Cibus Inc（US）
Recombinetics（US）
Sangamo Therapeutics（US）
Editas Medicine（US）
Precision BioSciences（US）
CRISPR Therapeutics（Switzerland）
Intellia Therapeutics, Inc（US）
Caribou Biosciences, Inc.（US）
Cellectis S.A（France）
AstraZeneca（UK）
Takara Bio Inc.（Japan）
Horizon Discovery Ltd.（Revvity, Inc.）（UK）
Danaher Corporation（US）
Transposagen Biopharmaceuticals, Inc.（US）
Genscript Biotech Corp（China）
New England Biolabs（US）
OriGene Technologies, Inc.（US）
bluebird bio, Inc（US）
Lonza（Switzerland）
Thermo Fisher Scientific, Inc.（US）

Product Code: SQSG35J2001

Global Genome Editing Market size was valued at USD 7.70 billion in 2022 and is poised to grow from USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast period (2024-2031).

Genome editing involves modifying an organism's DNA by cutting and adding or removing sequences to alter its genetic traits. This technique aims to endow cells with specific characteristics by making precise changes to their genome. Governments globally are investing more in genome editing research by providing funding and awards to both public and private sectors, as well as academic institutions. This increased support is driving positive growth in the genome editing market during the forecast period. Several factors are contributing to the expansion of the genome editing market. These include the rising prevalence of cancer and genetic disorders, the growing preference for personalized medicine, increased research and development expenditures, and advancements in biotechnology and pharmaceutical industries. The surge in both private and public funding, rapid progress in sequencing technologies, and advancements in genome editing techniques are also key drivers. The market has been significantly influenced by the adoption of CRISPR technology and the growing demand for synthetic genes across various biotechnology fields. Additionally, heightened competition among market players is accelerating the growth of the genome editing market. For example, Vertex Pharmaceuticals' $900 million agreement with CRISPR Therapeutics in April 2021 to develop and commercialize CRISPR-Cas9 gene-edited therapies for beta-thalassemia and sickle cell disease underscores the sector's dynamic nature. Such investments and initiatives are expected to further propel the growth of the genome editing market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segmental Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use, and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, and Others. Based on Delivery Method, the market is segmented into Ex-vivo, and In-Vivo. Based on Application, the market is segmented into Genetic Engineering, and Clinical Applications. Based on Mode, the market is segmented into Contract, and In-house. Based on end use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes, and Contract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Genome Editing Market

In recent years, governments globally have significantly invested in genomics, which has greatly advanced the field of genome editing. This support has allowed both academic and governmental institutions to conduct extensive research into genome editing and engineering. For example, the Ministry of Innovation, Science, and Industry (Science) awarded a $15 million grant to Genome Canada to fund 11 genomic research projects focused on health, agriculture, and environmental applications. Additionally, provincial governments, businesses, and research partners are contributing a combined total of $29.7 million to these initiatives, including research into ovarian and cervical cancer. These substantial investments have led to a considerable increase in genomics research projects. The resulting advancements and innovations are expected to drive growth in the genome editing market throughout the forecast period. The increased funding and support from various government bodies are fostering a robust research environment, which is likely to accelerate the development of new genome editing technologies and applications.

Restraints in the Global Genome Editing Market

Off-target effects associated with CRISPR-Cas9 are a significant concern in genome editing. The Cas9 enzyme creates double-stranded breaks in DNA, and any unintended nuclease activity can lead to mutations in non-target genes, potentially triggering oncogenesis. CRISPR-Cas9 can tolerate one to three mismatches in its target sequence, which increases the risk of off-target activity. This unintended activity can occur at a high frequency, with up to 50% of mutations happening at sites other than the intended target. For example, CRISPR might inadvertently target tumor suppressor genes or activate oncogenes. These issues have led to challenges in clinical trials, causing some to be halted. Regulatory bodies are now calling for more research to enhance the safety and precision of CRISPR-Cas9 technology.

Market Trends of the Global Genome Editing Market

The COVID-19 pandemic has spurred significant investments from major pharmaceutical and biotechnology companies, as well as from key players in the genomic sector, into vaccine research and development. This surge in investment is driven by the heightened demand for vaccines and antiviral treatments, which has placed genome editing and engineering technologies at the forefront of the industry. As a result, these advancements are anticipated to be a major force propelling the growth of the genome editing market in the coming years. The increased focus on developing effective vaccines and therapies underscores the growing importance of genome editing technologies in addressing global health challenges.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Genome Editing Market by Technology

Market Overview
(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Meganuclease
Others

Genome Editing Market by Delivery Method

Market Overview
Ex-vivo
In-Vivo

Genome Editing Market by Application

Market Overview
Genetic Engineering
- Cell Line Engineering
- Animal Genetic Engineering
- Plant Genetic Engineering
- Others
Clinical Applications
- Diagnostics
- Therapy Development

Genome Editing Market by Mode

Market Overview
Contract
In-house

Genome Editing Market by End-use

Market Overview
Biotechnology and pharmaceutical companies
Academic and government research institutes
Contract research organizations

Genome Editing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cibus Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recombinetics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Precision BioSciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caribou Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis S.A (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Discovery Ltd. (Revvity, Inc.) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transposagen Biopharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genscript Biotech Corp (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OriGene Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio, Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ゲノム編集の市場規模、シェア、成長分析、技術別、デリバリー方法別、用途別、モード別、最終用途別、地域別 - 産業予測、2024年～2031年

Genome Editing Market Size, Share, Growth Analysis, By Technology (/Cas9, TALENs/MegaTALs), By Delivery Method, By Application, By Mode, By End-use, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ゲノム編集市場：技術別

ゲノム編集市場：デリバリー方法別

ゲノム編集市場：用途別

ゲノム編集市場：モード別

ゲノム編集市場：最終用途別

ゲノム編集市場規模：地域別